

Small Molecules

Dabrafenib

MEK/ERK pathway inhibitor; Inhibits B-RAF V600E

Catalog # 73072
73074

10 mg
50 mg



Scientists Helping Scientists™ | WWW.STEMCELL.COM

TOLL FREE PHONE 1 800 667 0322 • PHONE +1 604 877 0713

INFO@STEMCELL.COM • TECHSUPPORT@STEMCELL.COM


FOR GLOBAL CONTACT DETAILS VISIT OUR WEBSITE

Product Description

Dabrafenib is a reversible, selective, and ATP-competitive inhibitor of B-RAF with higher potency towards V600E mutant B-RAF over wild-type B-RAF or C-RAF, with IC₅₀ values of 0.8, 3.2, and 5 nM, respectively (Laquerre et al.; Menzies et al.).

Molecular Name: Dabrafenib
Alternative Names: GSK 2118436; Dabarefenib; Tafinlar®
CAS Number: 1195765-45-7
Chemical Formula: C₂₃H₂₀F₃N₅O₂S₂
Molecular Weight: 519.6 g/mol
Purity: ≥ 98%
Chemical Name: N-[3-[5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl]-2-fluorophenyl]-2,6-difluorobenzenesulfonamide

Structure:



Properties

Physical Appearance: A crystalline solid
Storage: Product stable at -20°C as supplied. Protect from prolonged exposure to light. For product expiry date, please contact techsupport@stemcell.com.
Solubility: · DMSO ≤ 55 mM
· Absolute ethanol ≤ 2 mM
For example, to prepare a 10 mM stock solution in DMSO, resuspend 10 mg in 1.92 mL of DMSO.

Prepare stock solution fresh before use. Information regarding stability of small molecules in solution has rarely been reported, however, as a general guide we recommend storage in DMSO at -20°C. Aliquot into working volumes to avoid repeated freeze-thaw cycles. The effect of storage of stock solution on compound performance should be tested for each application.

Compound has low solubility in aqueous media. For use as a cell culture supplement, stock solution should be diluted into culture medium immediately before use. Avoid final DMSO concentration above 0.1% due to potential cell toxicity.

Published Applications

CANCER RESEARCH

- Decreases ERK phosphorylation and inhibits cell proliferation in cells expressing the B-RAF mutation V600E. Prevents tumor growth in mouse xenograft models of B-RAF(V600E) human melanoma and colon cancer (Rheault et al.).

DISEASE MODELING

- Alleviates acetaminophen-induced liver injury through distinct nanomolar inhibition of receptor-interacting protein (RIP3) in mice (Li et al.).

References

- Li J-X et al. (2014) The B-Raf(V600E) inhibitor dabrafenib selectively inhibits RIP3 and alleviates acetaminophen-induced liver injury. *Cell Death Dis* 5: e1278.
- Menzies AM et al. (2012) Dabrafenib and its potential for the treatment of metastatic melanoma. *Drug Des Devel Ther* 6: 391–405.
- Rheault TR et al. (2013) Discovery of Dabrafenib: A Selective Inhibitor of Raf Kinases with Antitumor Activity against B-Raf-Driven Tumors. *ACS Med Chem Lett* 4(3): 358–62.

Related Small Molecules

For a complete list of small molecules available from STEMCELL Technologies, please visit our website at www.stemcell.com/smallmolecules or contact us at techsupport@stemcell.com.

STEMCELL TECHNOLOGIES INC.'S QUALITY MANAGEMENT SYSTEM IS CERTIFIED TO ISO 13485. PRODUCTS ARE FOR RESEARCH USE ONLY AND NOT INTENDED FOR HUMAN OR ANIMAL DIAGNOSTIC OR THERAPEUTIC USES UNLESS OTHERWISE STATED.

Copyright © 2017 by STEMCELL Technologies Inc. All rights reserved including graphics and images. STEMCELL Technologies & Design, STEMCELL Shield Design and Scientists Helping Scientists are trademarks of STEMCELL Technologies Canada Inc. Tafinlar is a registered trademark of Novartis Pharma AG or its affiliates. All other trademarks are the property of their respective holders. While STEMCELL has made all reasonable efforts to ensure that the information provided by STEMCELL and its suppliers is correct, it makes no warranties or representations as to the accuracy or completeness of such information.